Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials
Mattía Galli(Maria Cecilia Hospital), Dominick J. Angiolillo(Jacksonville University), Naveen L. Pereira(Mayo Clinic), Roxana Mehran(Icahn School of Medicine at Mount Sinai), Francesco Franchi(Florida College), Fabiana Rollini(Florida College), Filippo Crea(Università Cattolica del Sacro Cuore), Behnood Bikdeli(NewYork–Presbyterian Hospital), Larisa H. Cavallari(University of Florida), Giovanni Maria Vescovo(Ospedale dell' Angelo), Giuseppe Biondi‐Zoccai(Sapienza University of Rome), Dirk Sibbing(LMU Klinikum), Stefano Benenati(University of Genoa), C. Michael Gibson(Brigham and Women's Hospital), Davide Capodanno, Jurriën M. ten Berg
Cited by 150
Related Papers
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
2024 ESC Guidelines for the management of chronic coronary syndromes
|European Heart Journal|2024|2.3k